Medicinova Inc (MNOV)

$1.56 +0.01 (0.65%)
Market Cap 76.52M
Revenue (ttm) 0.00
Net Income (ttm) -11.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 99,600
Avg Vol 1,215,790
Day's Range N/A - N/A
Shares Out 49.05M
Stochastic %K 79%
Beta 0.48
Analysts Strong Sell
Price Target $7.00

Company Profile

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical my...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 373 1500
Fax: 858 404 0048
Address:
4275 Executive Square, Suite 300, La Jolla, United States
JohnTrack
JohnTrack Dec. 2 at 7:18 PM
$MNOV to the moonnn!!
1 · Reply
doledav
doledav Dec. 2 at 12:38 PM
$MNOV it’s wild, if this technology works to reverse atherosclerosis this drug would be worth billions, high cholesterol is a huge field due to heart disease
0 · Reply
thepalace2007
thepalace2007 Dec. 2 at 3:03 AM
$MNOV press release after hours
0 · Reply
JohnTrack
JohnTrack Dec. 2 at 12:53 AM
$MNOV news tick on this name... https://www.rapidticker.com/news/mnov-message-from-the-ceo-to-cdbdc4
0 · Reply
Mahdinur
Mahdinur Nov. 30 at 5:48 PM
$AREB $PRPH $MNOV $ELBM $GRI big money
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Nov. 30 at 5:47 PM
Small-Caps with Catalysts this week: 👇👇 ( $AREB, $PRPH, $MNOV, $ELBM, etc...) #NASDAQ #NYSE
0 · Reply
thepalace2007
thepalace2007 Nov. 25 at 6:06 PM
$MNOV super
0 · Reply
Lionish
Lionish Nov. 19 at 12:18 AM
$MNOV Solid cash position and free of long term debt. Standby Equity Purchase Agreement. Addressing unmet medical needs. Making solid progress. A biotech gem like no other. GL!
0 · Reply
thepalace2007
thepalace2007 Nov. 13 at 1:19 AM
$MNOV keep accumulating this will fly with news on earnings
1 · Reply
Zackpedia
Zackpedia Nov. 12 at 8:15 PM
$MNOV
0 · Reply
Latest News on MNOV
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

Nov 18, 2025, 6:00 AM EST - 19 days ago

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

Nov 6, 2025, 6:00 PM EST - 4 weeks ago

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

Oct 30, 2025, 7:00 PM EDT - 5 weeks ago

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

Oct 6, 2025, 8:00 AM EDT - 2 months ago

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

MediciNova Provides Shareholder Update on Key Developments

Sep 8, 2025, 9:00 AM EDT - 3 months ago

MediciNova Provides Shareholder Update on Key Developments

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:00 AM EDT - 3 months ago

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

Aug 26, 2025, 7:00 PM EDT - 3 months ago

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

Jul 31, 2025, 7:30 PM EDT - 4 months ago

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

Jul 24, 2025, 6:00 AM EDT - 4 months ago

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

Apr 14, 2025, 7:00 PM EDT - 8 months ago

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

Apr 8, 2025, 7:00 PM EDT - 8 months ago

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

Dec 5, 2024, 6:00 PM EST - 1 year ago

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

Nov 14, 2024, 6:00 PM EST - 1 year ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

Nov 11, 2024, 6:00 PM EST - 1 year ago

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

Oct 23, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Sep 30, 2024, 9:00 AM EDT - 1 year ago

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

Sep 9, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

Sep 3, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

Aug 29, 2024, 7:00 PM EDT - 1 year ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

MediciNova Chief Business Officer David H. Crean, Ph.D.

Jun 20, 2024, 6:00 AM EDT - 1 year ago

MediciNova Chief Business Officer David H. Crean, Ph.D.

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

Jun 5, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Jun 3, 2024, 6:00 AM EDT - 1 year ago

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

May 28, 2024, 6:00 AM EDT - 1 year ago

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

May 20, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

May 14, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

May 7, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Apr 2, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Mar 26, 2024, 7:00 PM EDT - 1 year ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

Mar 20, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

Mar 12, 2024, 6:30 AM EDT - 1 year ago

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

Jan 17, 2024, 6:00 AM EST - 2 years ago

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

Dec 21, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Dec 6, 2023, 6:00 PM EST - 2 years ago

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Nov 19, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

Oct 27, 2023, 1:00 AM EDT - 2 years ago

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

Oct 10, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

MediciNova Receives Gene Therapy Milestone Payment

Oct 4, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives Gene Therapy Milestone Payment

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Sep 27, 2023, 7:00 PM EDT - 2 years ago

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

Aug 17, 2023, 7:00 PM EDT - 2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

Aug 16, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

Aug 15, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

Aug 14, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

Jun 29, 2023, 6:00 AM EDT - 2 years ago

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

May 14, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

Apr 30, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Mar 9, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

Feb 20, 2023, 6:00 PM EST - 3 years ago

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

Feb 8, 2023, 6:00 PM EST - 3 years ago

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

Jan 30, 2023, 6:00 PM EST - 3 years ago

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

Jan 12, 2023, 6:00 PM EST - 3 years ago

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

JohnTrack
JohnTrack Dec. 2 at 7:18 PM
$MNOV to the moonnn!!
1 · Reply
doledav
doledav Dec. 2 at 12:38 PM
$MNOV it’s wild, if this technology works to reverse atherosclerosis this drug would be worth billions, high cholesterol is a huge field due to heart disease
0 · Reply
thepalace2007
thepalace2007 Dec. 2 at 3:03 AM
$MNOV press release after hours
0 · Reply
JohnTrack
JohnTrack Dec. 2 at 12:53 AM
$MNOV news tick on this name... https://www.rapidticker.com/news/mnov-message-from-the-ceo-to-cdbdc4
0 · Reply
Mahdinur
Mahdinur Nov. 30 at 5:48 PM
$AREB $PRPH $MNOV $ELBM $GRI big money
0 · Reply
BigTimePennyStocks
BigTimePennyStocks Nov. 30 at 5:47 PM
Small-Caps with Catalysts this week: 👇👇 ( $AREB, $PRPH, $MNOV, $ELBM, etc...) #NASDAQ #NYSE
0 · Reply
thepalace2007
thepalace2007 Nov. 25 at 6:06 PM
$MNOV super
0 · Reply
Lionish
Lionish Nov. 19 at 12:18 AM
$MNOV Solid cash position and free of long term debt. Standby Equity Purchase Agreement. Addressing unmet medical needs. Making solid progress. A biotech gem like no other. GL!
0 · Reply
thepalace2007
thepalace2007 Nov. 13 at 1:19 AM
$MNOV keep accumulating this will fly with news on earnings
1 · Reply
Zackpedia
Zackpedia Nov. 12 at 8:15 PM
$MNOV
0 · Reply
Hanmer
Hanmer Nov. 10 at 3:28 PM
$MNOV this one is ready to launch!!!!
0 · Reply
Zackpedia
Zackpedia Nov. 7 at 6:02 PM
$MNOV You could’ve sold when I alerted and bought back at 1.4 now if you wanted, hit Follow and subscribe to get my alerts on time and make money
0 · Reply
Hanmer
Hanmer Nov. 7 at 1:35 PM
$MNOV we were over $1.60 this morning premarket already!!!
1 · Reply
Stackingg
Stackingg Nov. 7 at 1:34 PM
$MNOV
0 · Reply
TCzeck
TCzeck Nov. 7 at 5:38 AM
$MNOV BOOM!
0 · Reply
Hanmer
Hanmer Nov. 7 at 2:11 AM
$MNOV she’s looking sexy tonight!!!
0 · Reply
Lionish
Lionish Nov. 7 at 12:11 AM
$MNOV Up over 20% again in Tokyo now
0 · Reply
thepalace2007
thepalace2007 Nov. 6 at 11:38 PM
$MNOV big money is loading and so should you $6+ coming soon
0 · Reply
Hanmer
Hanmer Nov. 6 at 11:03 PM
$MNOV sky rockets in flight, afternoon delight!!!!
0 · Reply
Achila2018
Achila2018 Nov. 5 at 9:02 PM
$MNOV moving sideways ... hmmm
0 · Reply
Hanmer
Hanmer Nov. 5 at 2:55 AM
$MNOV I’m loving the overnight trading up 18%!!!
0 · Reply
scubarat
scubarat Nov. 4 at 2:47 PM
$MNOV when a company pays to publish the same exact news twice in 5 days, that doesn’t look good. 10/31 and today 11/4 they publish news of their $9 price target. In other words, these guys are pumping so be ready for a quick offering from them the first big day they have again.
1 · Reply